[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Atridia Pty Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100620496","phase-1-a-trial-of-hrs-6209-205-to-evaluate-the-safety-tolerability-pharmacokinetics-and-efficacy-of-hrs-6209-in-combination-therapy-in-subjects-with-hr-positiveher2-negative-cancer-100620496",false,"NCT07358377","A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive\u002FHER2-Negative Cancer","An Open-Label, Multi-Center Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant or Letrozole in Patients With Solid Tumor","Inclusion Criteria\n\n1. Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.\n2. Adequate bone marrow and other vital organ functions\n3. Adequate liver function tests\n4. HR-positive or HER2-negative solid tumor patients\n\nExclusion Criteria\n\n1. Plan to receive any other anti-tumor therapy during the study.\n2. Active brain metastases .\n3. Have poorly controlled or severe cardiovascular disease, including (1) congestive heart failure.\n4. Previous use of fulvestrant\n5. clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding.\n6. With uncontrollable chronic systemic complications (such as severe chronic lung, liver, kidney, or heart disease).\n7. With acute or active tuberculosis infection requiring medication.\n8. Pregnant or lactating women, or females planning to become pregnant During the study.\n9. Known history of clinically significant liver disease, untreated active hepatitis (hepatitis B, defined as hepatitis B virus surface antigen \\[HBsAg\\] or hepatitis B core antibody \\[HBcAb\\] positive","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive\u002FHER2-Negative solid tumor.",[26],"Breast Cancer","RECRUITING","2026-08-10",{"date":30,"type":31},"2026-08-11","ACTUAL",{"date":33,"type":31},"2026-05-15",{"date":35,"type":20},"2027-11-10",{"name":37,"class":38},"Atridia Pty Ltd.","INDUSTRY",6,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100646715","early-phase-1-a-trial-of-hrs-3095-in-healthy-volunteers-100646715","NCT07686484","A Trial of HRS-3095 in Healthy Volunteers","A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-3095 in Healthy Participants","Main inclusion criteria\n\n1. Healthy white participants.\n2. Male or female aged between 18 years and 55 years (inclusive)\n3. Ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written informed consent, be able to comply with all the requirements, and able to complete the study.\n4. Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, body mass index (BMI) between 19.0 and 30.0 kg\u002Fm2 (inclusive) at screening.\n5. Men and WOCBP must agree to take highly effective contraceptive methods\n\nMain exclusion Criteria\n\n1. History or evidence of clinically significant disorders.\n2. Individuals with a history of drug allergies, specific allergies, or known history or suspected of being allergic to the study drug or same class drug or any component of it.\n3. Receipt of medical devices or another investigational drug within 3 months or 5 half-lives, whichever is longer prior to screening.\n4. History of excessive smoking in the past 1 month prior to screening\n5. History of illicit or prescription drug abuse or addiction within 1 year of screening, or positive urine drug screen at baseline.\n6. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply",true,"55 Years",{"count":50,"type":20},36,[52],"EARLY_PHASE1","The purpose of this study is to assess safety, PK, Pharmacodynamic profile of a single dose of HRS-3095 in healthy participants",[55],"Chronic Spontaneous Urticaria","2026-08-05",{"date":58,"type":31},"2026-08-07",{"date":60,"type":31},"2026-07-27",{"date":62,"type":20},"2026-10-15",{"name":37,"class":38},1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":72,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100579942","phase-1-a-trial-of-hrs-5041-103-to-evaluate-the-safety-tolerability-pharmacokinetics-and-efficacy-of-hrs-5041-in-subjects-with-metastatic-castration-resistant-prostate-cancer-100579942","NCT06830850","A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer","A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer","IInclusion Criteria\n\n1. Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.\n2. Adequate bone marrow and other vital organ functions\n3. Adequate liver function tests\n4. Metastatic Castration-resistant Prostate Cancer\n\nExclusion Criteria\n\n1. Plan to receive any other anti-tumor therapy during the study.\n2. Receipt of any chemotherapy, targeted therapy, immunotherapy, live\u002Fattenuated vaccination, radiotherapy or surgery within 4 weeks prior to the first dosing of this study.\n3. Uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\> 150 mmHg and\u002For diastolic blood pressure \\[DBP\\] \\> 100 mmHg with regular anti-hypertension therapy).\n4. Factors that may affect the oral administration of the IP (swallow difficulty, chronic diarrhea, and bowel obstruction, etc.), or active gastrointestinal (GI) disease or other disease which may affect the absorption, distribution, metabolism, or elimination of IP.\n5. Known history of drug allergies, specific allergies (such as asthma, urticaria, eczema, etc.).\n6. Active heart disease within 6 months prior to the first dosing of this study.\n7. Medical history of other malignant tumor within 5 years prior to dosing.\n8. Positive hepatitis B virus (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV-Ab), or syphilis or severe infections which need treatment.","MALE",{"count":74,"type":20},25,[23],"To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.",[78],"Metastatic Castration Resistant Prostate Cancer","2026-01-13",{"date":81,"type":31},"2026-01-15",{"date":83,"type":31},"2025-06-15",{"date":85,"type":20},"2027-03-15",{"name":37,"class":38},11,""]